Cagent Vascular has announced two significant milestones, marking a pivotal moment for the endovascular technology company. It successfully completed the first human use of its Serranator® SONIC Intravascular Lithotripsy (IVL) System. This clinical achievement was coupled with the closing of an oversubscribed $41 million Series D financing round to fuel future growth.
A Novel Dual-Modality Approach
The Serranator SONIC IVL System represents a significant advancement by combining two distinct technologies into a single platform. It integrates the company's Serranator Serration Remodeling Therapy (SRT) with a SONIC lithotripsy generator. This dual-modality device transmits ultrasonic waves through serrated metal elements to effectively treat calcified plaque.
This innovative system is designed for ease of use, being fully disposable and requiring no separate capital equipment. Physicians can tailor energy delivery in real time, offering greater control during procedures. The platform is positioned to address a broader range of complex lesions than conventional IVL systems, targeting a market estimated at $17 billion.
Successful First-in-Human Clinical Trials
The initial procedures were performed in Uzbekistan as part of the company's REMODEL I study. This prospective, multicenter trial is designed to evaluate the system's safety and performance in femoropopliteal and infrapopliteal arteries. The study also includes clinical centers in New Zealand and Australia, expanding its international scope.
Early results from the first cases demonstrated successful calcium modification and significant lesion remodeling, as observed through advanced imaging. Dr. Steven Kum, one of the performing physicians, noted the platform's impressive safety and effectiveness in complex cases. He highlighted the substantial lumen gain and improved vessel compliance achieved during the procedures.
Securing a Financial Foundation for Growth
To support its ambitious clinical and commercial goals, Cagent Vascular secured $41 million in a Series D financing round. The funding was co-led by prominent investors U.S. Venture Partners (USVP) and Astoria Health Investors. This substantial investment underscores strong confidence in the company's technology and strategic direction.
Proceeds from the financing are earmarked for key strategic initiatives, including a global pivotal trial and the system's commercial launch. The funds will also support the development of a SONIC IVL platform for coronary arteries. This builds upon the company's existing commercial foundation established with its Serranator portfolio.
Leadership and Investor Outlook
Chief Executive Officer Brian Walsh emphasized that the SONIC IVL System resolves a long-standing dilemma for physicians. He stated that clinicians no longer have to choose between the separate technologies of SRT and IVL. For the first time, both mechanisms are available in a single device for a single procedure.
Investor confidence was echoed by Casey Tansey of USVP, who described the platform as a next-generation IVL technology. He noted that the company is building on over 40,000 safe and effective Serranator procedures. This track record positions Cagent Vascular to execute successfully in a high-growth market segment.
Cagent Vascular's recent achievements signal a major step forward in treating complex peripheral and coronary artery disease. The successful first-in-human use of its dual-modality system, backed by a significant $41 million investment, validates its innovative approach. The company is now well-positioned to advance its clinical programs and expand its commercial footprint globally.